Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development Service Platform
Drug Discovery Platform
Pharmaceutical Research Platform
Preclinical Research Services
Botanical Drug Preclinical R&D Technology Platform
02 Innovative Drug Services
ADC R&D Service Platform
PROTAC R&D Service Platform
mRNA Vaccine Bioanalysis Platform
Non-clinical Research for Cellular Immunotherapies
Nucleic Acid Drug R&D Platform
Peptide Drug Conjugate (PDC) R&D Service Platform
Antibody R&D Service
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Platform
Metabolite Identification (MetID) Service Platform
Drug Forming Research Platform
Flow Cytometry Technology Platform
SEND Format Conversion Platform
Flow Sorting Platform
NanoString nCounter Detection Platform
Routes of Drug Administration Platform
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model Evaluation Platform
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
05 Advanced Preparation R&D
Inhalation drug R&D platform
Ophthalmic drug R&D platform
Skin Topical Preparation R&D Platform
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Recruitment
Talent Development
Talent Development
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center
Case Studies Clients Testimonials Downloads Partnerships Intellectual Property Protection Newsletters
HomeClient CenterMedicilon Support
IND 100 Publications
Mar 14,2022
Medicilon assisted China's First Original Research Highly Selective EP4 Receptor Antagonist YY001 Obtained Clinical Approval
Shanghai Medicilon Inc. (Medicilon) provided GLP-compliant toxicology DRF tests and application materials for the research and development of YY001, which accelerating the project to get into Phase 1 clinical trials.
See More
Medicilon assisted China's First Original Research Highly Selective EP4 Receptor Antagonist YY001 Obtained Clinical Approval
Feb 28,2022
Medicilon Won Praise and Awards From Many Partners
Leading Tac Pharma's PROTAC drug project is a first-in-class research and development project that challenges anti-tumor and autoimmune diseases. In the cooperation with Medicilon, the Medicilon's DMPK team actively communicated with Leading Tac which helped customers solve a series of research and development problems such as large molecular weight, ensuring the completion of the project.
See More
Medicilon Won Praise and Awards From Many Partners
Feb 17,2022
World's First Inhaled Nanobody Drug LQ036
In the development process of the world's first inhaled nanobody drug for the treatment of moderate and severe asthma, Medicilon assists LQ036 to complete the quality research services of inhaled preparations.
See More
World's First Inhaled Nanobody Drug LQ036
Jan 24,2022
Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
On December 28, 2021, Hangzhou DAC Biotechnology Co., Ltd. (DAC Biotech) DXC007 project was successfully approved for clinical trials. DXC007 is the fourth ADC drug approved for clinical use by DAC Biotech, and it is also the fourth ADC drug that Shanghai Medicilon Inc. (Medicilon) to help DAC Biotech successfully getting approval.
See More
Medicilon Assisted DAC Biotechnology's Fourth ADC Drug DXC007 Getting Approved for Clinical Use
Jan 11,2022
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
On December 28, 2021, the new generation of CDK2/4/6 small molecule inhibitor RGT-419B independently developed by Regor Therapeutics Group (Regor) was approved by the U.S. Food and Drug Administration (FDA).
See More
Medicilon Assisted Regor Therapeutics Group's New-generation Tumor-targeting Inhibitor RGT-419B Getting Approved for Clinical Use
Nov 22,2021
Within 10 days, three Bispecific Antibody Drugs Assisted by Medicilon were Approved!
On October 19, Bio-Thera's new double-antibody drug BAT7104 was granted implicit approval for clinical trials.
See More
Within 10 days, three Bispecific Antibody Drugs Assisted by Medicilon were Approved!
Oct 28,2021
[Medicilon Assist] Bio-Thera's Bispecific Antibody BAT7104 has been Approved for Clinical Trials
​Recently, Bio-Thera's PD-L1/CD47 bispecific antibody BAT7104 injection has been granted implicit permission for clinical trials, and the approved indication is advanced malignant tumors. It is reported that BAT7104 has started overseas clinical research.
See More
[Medicilon Assist] Bio-Thera's Bispecific Antibody BAT7104 has been Approved for Clinical Trials
Sep 22,2021
Targeting IL-23, Medicilon Assists the Development of a Variety of New Drugs for Psoriasis
IL-23 is mainly produced by activated dendritic cells, macrophages and monocytes. It is a new member of the IL-12 heterodimeric cytokine family.
See More
Targeting IL-23, Medicilon Assists the Development of a Variety of New Drugs for Psoriasis
Sep 07,2021
Medicilon's antibody drug R&D technology platform assisted Bio-Thera Solutions, Ltd's two projects to get the clinical approvals
Recently, Bio-Thera Solutions, Ltd. (Bio-Thera)'s BAT6021 injection and BAT6005 injection of innovative drugs have been approved for clinical use, which means the new progress has been made in the field of tumor treatment. Recently, Bio-Thera Solutions, Ltd. (Bio-Thera)'s BAT6021 injection and BAT6005 injection of innovative drugs have been approved for clinical use, which means theRead more
See More
Medicilon's antibody drug R&D technology platform assisted Bio-Thera Solutions, Ltd's two projects to get the clinical approvals
Sep 07,2021
Medicilon assists Chipscreen Biosciences' CS12192 to be approved by the FDA
On August 28, 2021, the FDA recently approved the CS12192, a new drug clinical trial application for the treatment of Graft Versus Host Disease (GVHD) independently developed by Chipscreen Biosciences (Chipscreen).  Previously, the drug has obtained clinical approval in China. It is worth mentioning that Shanghai Medicilon Inc. (Medicilon) provides comprehensive preclinical research including pharmacokineticsRead more
See More
Medicilon assists Chipscreen Biosciences' CS12192 to be approved by the FDA
Stock Code
688202

Global

Address: 470 Wildwood Ave, Woburn, MA 01801 (America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->